Subscribe
Home
Issues
Online First
Latest Issue
Issue Archive
Special Issues
Browse By Topic
Personalized Medicine
Economics & Value
FDA Approvals, News & Updates
COVID-19
Cholangiocarcinoma
View All Topics ›
Conference Correspondent
SABCS 2023 - HER2+ MBC
ASCO 2023 - Breast Cancer
Web Exclusives
Web Exclusive Articles
Videos
Interview with the Innovators
Prostate Cancer Diagnostics Monthly Minutes
Webinars
Quick Quizzes
Press Releases
AVBCC
Association for Value-Based Cancer Care
VBCM
Value-Based Care in Myeloma
Issues
2014
April 2014, Vol 5, No 3
April 2014, Vol 5, No 3
Quality Research and Patient Safety
April 2014, Vol 5, No 3
Quality Research and Patient Safety Abstract from the 4th Annual AVBCC Conference.
Read Article
Policy, Advocacy, and Economy Abstacts
April 2014, Vol 5, No 3
Policy, Advocacy, and Economy Abstacts from the 4th Annual AVBCC Conference.
Read Article
Patient and Survivor Care Abstracts
April 2014, Vol 5, No 3
Patient and Survivor Care Abstracts from the 4th Annual AVBCC Conference.
Read Article
Oncology Practice Management, Navigation, & Advocacy Day Abstracts
Patient Navigation
,
Practice Management
,
Policies & Guidelines
,
Value Peer-spectives
April 2014, Vol 5, No 3
Oncology Practice Management, Navigation, & Advocacy Day Abstracts from the 4th Annual AVBCC Conference.
Read Article
Models of Care Delivery Abstracts
April 2014, Vol 5, No 3
Models of Care Delivery Abstracts from the 4th Annual AVBCC Conference.
Read Article
Innovation in Practice Management Abstract
Practice Management
,
Value Peer-spectives
April 2014, Vol 5, No 3
Innovation in Practice Management Abstract from the 4th Annual AVBCC Conference.
Read Article
Improving Patient Access, Initiation, and Adherence Abstract
By
Jayson Slotnik, JD, MPH
April 2014, Vol 5, No 3
Improving Patient Access, Initiation, and Adherence Abstract from the 4th Annual AVBCC Conference.
Read Article
Benefit Design and Coverage Trends Abstract
By
Jayson Slotnik, JD, MPH
April 2014, Vol 5, No 3
Benefit Design and Coverage Trends Abstract from the 4th Annual AVBCC Conference
Read Article
Advocacy and Community Involvement Abstract
By
Jayson Slotnik, JD, MPH
April 2014, Vol 5, No 3
Advocacy and Community Involvement Abstract from the 4th Annual AVBCC Conference
Read Article
Updated NCCN Melanoma Guideline Adds BRAF Inhibitor and MEK Inhibitor to First-Line Targeted Therapeutic Options
By
Wayne Kuznar
NCCN 2014 Conference
April 2014, Vol 5, No 3
Hollywood, FL—The updated National Comprehensive Cancer Network (NCCN) guidelines for the management of melanoma now include the BRAF inhibitor dabrafenib (Tafinlar) as a Category 1 recommendation for the primary treatment of patients with metastatic melanoma and
BRAF
mutation, as well as the use of the mitogen-activated protein kinase (MEK) inhibitor trametinib (Mekinist) for the treatment of patients with melanoma and
BRAF
mutation. These 2 drugs, which received US Food and Drug Administration (FDA) approval last year, are now added to the NCCN targeted therapies for the treatment of patients with advanced or metastatic melanoma.
Read Article
Page 1 of 3
1
2
3
View the Latest Issue of VBCC
Read Issue
Top Trending Articles
1.
Navigating the Complex Landscape of Oral Cancer Medication
2.
Luspatercept Yields Improved Transfusion Independence Compared With Epoetin Alfa in Patients With Lower-Risk MDS
Phoebe Starr
3.
New NCCN Guidelines for CLL/SLL Include Second-Generation BTK Inhibitors
Wayne Kuznar
Home
Issues
Online First
Latest Issue
Issue Archive
Special Issues
Browse By Topic
Personalized Medicine
Economics & Value
FDA Approvals, News & Updates
COVID-19
Cholangiocarcinoma
View All Topics ›
Conference Correspondent
SABCS 2023 - HER2+ MBC
ASCO 2023 - Breast Cancer
Web Exclusives
Web Exclusive Articles
Videos
Interview with the Innovators
Prostate Cancer Diagnostics Monthly Minutes
Webinars
Quick Quizzes
Press Releases
AVBCC
Association for Value-Based Cancer Care
VBCM
Value-Based Care in Myeloma